Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
about
Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirusNovel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesMedical and virological aspects of ocular human immunodeficiency virus infection for the ophthalmologist.Resistance of human cytomegalovirus to antiviral drugs.Virus infections of the eye.Clinical uses of cidofovir.Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragmentsSulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus.Antimicrobial strategies in the care of organ transplant recipientsSingle amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovHuman cytomegalovirus infection inhibits G1/S transition.Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.Synthesis and antiviral activities of 3-aralkylthiomethylimidazo[1,2-b]pyridazine derivatives."The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge.A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activityVirucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein BPatterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene.Cidofovir in the treatment of cytomegaloviral disease.Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.
P2860
Q24519013-F3637BB4-9FA7-4D03-AE7D-381353202704Q28343467-AA17CDC7-CD4A-4D98-B4A5-1B67031FDAA7Q28367722-62FC311F-CC9B-4B2B-8295-09F127FE3F57Q33569593-2E253064-B879-4F8C-899C-4F5703774326Q33588911-FF6B19A2-F46E-4382-92A7-D29E4E8CC33AQ33682990-375B9FE0-79FD-4852-A631-E2C7B27D22FFQ33867391-4B045651-ADBC-44D9-9E1C-B25FF3BC0F17Q33977394-63FD6768-C09E-4109-BF79-04B71B894E05Q35807437-6892D4F3-C28E-45A9-8DA8-B6BBE7A8B883Q39582502-9D662FC0-1186-4C3A-9C4D-68D3E3262731Q39666949-ACF1A1A2-82C5-4C61-9D20-E68C5DE710D8Q39865375-F2902D2C-129B-403B-8296-5F6542314469Q39873608-4BBCCE29-ED05-46E3-AEAF-BD83B378AAB6Q39878302-665A4E17-4EE8-47CC-BA3C-6609AF3DF51EQ40062049-F3C0CFF5-B9DE-42F0-B621-427C0F85EBDCQ40622209-86F3536F-79AF-4729-8A87-08B0460DCDA8Q40720231-ADCDC781-3E46-4DBA-9FD8-2C21DC2DBE6AQ40852958-1D53559C-F90E-4324-AFC2-AB9ADCA7BDCBQ42147352-0B662959-DC11-48AF-B3B5-3DA20770EBDAQ42425029-90AD322F-CE51-4DD4-B5E0-58AA5AB49E35Q44570856-31BC5D1B-A1C9-43A1-A09D-2D32FB9ED997Q49980151-C22CBF87-CB73-4B87-A91F-FDD8006BAF19Q54115801-8E29537C-D377-4BA8-8872-9C18F5DEA706Q54257052-28BCEFD6-6EE0-4585-9DC2-812AAD17CA96
P2860
Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@en
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@nl
type
label
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@en
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@nl
prefLabel
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@en
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@nl
P356
P1476
Isolation of foscarnet-resista ...... vity to other antiviral drugs.
@en
P2093
P304
P356
10.1093/INFDIS/164.4.781
P407
P577
1991-10-01T00:00:00Z